A number of investment brokers have recently updated their price targets on shares of Array BioPharma Inc. (ARRY).

Most recent broker ratings

02/03/2016 – Array BioPharma Inc. had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 7 price target on the stock.

12/17/2015 – Array BioPharma Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 6 price target on the stock.

12/17/2015 – Array BioPharma Inc. had its “buy” rating reiterated by analysts at Cantor Fitzgerald.

12/16/2015 – Array BioPharma Inc. had its “buy” rating reiterated by analysts at Piper Jaffray.

05/06/2015 – Array BioPharma Inc. was upgraded to “strong-buy” by analysts at Zacks. They now have a USD 8.25 price target on the stock.

01/26/2015 – Array BioPharma Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 9 price target on the stock.

01/26/2015 – Array BioPharma Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 10 price target on the stock.

12/15/2014 – Array BioPharma Inc. had its “buy” rating reiterated by analysts at Cantor. They now have a USD 9 price target on the stock.

12/04/2014 – Array BioPharma Inc. had its “market perform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 5 price target on the stock.

The share price of Array BioPharma Inc. (ARRY) was down -2.33% during the last trading session, with a day high of 3.09. 1619074 shares were traded on Array BioPharma Inc.’s last session.

The stock’s 50 day moving average is 3.06 and its 200 day moving average is 3.55. The stock’s market capitalization is 421.41M. Array BioPharma Inc. has a 52-week low of 2.38 and a 52-week high of 8.04.

View other investors thoughts on Array BioPharma Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.